AR083017A1 - Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol - Google Patents

Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol

Info

Publication number
AR083017A1
AR083017A1 ARP110103389A ARP110103389A AR083017A1 AR 083017 A1 AR083017 A1 AR 083017A1 AR P110103389 A ARP110103389 A AR P110103389A AR P110103389 A ARP110103389 A AR P110103389A AR 083017 A1 AR083017 A1 AR 083017A1
Authority
AR
Argentina
Prior art keywords
etil
productions
imidazol
methylphenyl
methanol
Prior art date
Application number
ARP110103389A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083017(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR083017A1 publication Critical patent/AR083017A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Composiciones farmacéuticas y usos.Reivindicación 1: Un compuesto de la fórmula (1), sus enantiómeros individuales, sus diastereoisómeros, sus hidratos, sus solvatos, sus formas de cristal, sus isómeros individuales, sus tautómeros individuales o una sal farmacéuticamente aceptable de la misma, en la que R1 es H o alquil C1-3; R2 es H o alquil C1-3; R3 es H, alquil C1-10, heterociclo o aril; y R es alquil C1-10, heterociclo o aril.
ARP110103389A 2010-09-16 2011-09-16 Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol AR083017A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16

Publications (1)

Publication Number Publication Date
AR083017A1 true AR083017A1 (es) 2013-01-23

Family

ID=44675870

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP110103391A AR083019A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades de la retina, articulo de fabricacion y composicion farmaceutica que lo comprenden
ARP110103389A AR083017A1 (es) 2010-09-16 2011-09-16 Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
ARP110103390A AR083018A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden
ARP110103392A AR083020A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP110103391A AR083019A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades de la retina, articulo de fabricacion y composicion farmaceutica que lo comprenden

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP110103390A AR083018A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para la reduccion de la presion intraocular, articulo de fabricacion y composicion farmaceutica que lo comprenden
ARP110103392A AR083020A1 (es) 2010-09-16 2011-09-16 Uso de un compuesto de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para preparar un medicamento util para tratar enfermedades y afecciones de la piel, articulo de fabricacion y composicion farmaceutica que lo comprenden

Country Status (29)

Country Link
US (9) US8653123B2 (es)
EP (13) EP2616066B1 (es)
JP (4) JP6045495B2 (es)
KR (7) KR101840501B1 (es)
CN (5) CN103221045A (es)
AR (4) AR083019A1 (es)
AU (4) AU2011301847B2 (es)
BR (4) BR112013006320B1 (es)
CA (8) CA3116249A1 (es)
CL (4) CL2013000736A1 (es)
CY (3) CY1121024T1 (es)
DK (9) DK3050563T3 (es)
ES (10) ES2607084T3 (es)
HK (5) HK1185540A1 (es)
HU (5) HUE047476T2 (es)
IL (4) IL225282A0 (es)
MX (4) MX2013003004A (es)
MY (4) MY161607A (es)
NZ (1) NZ608751A (es)
PL (7) PL3338777T3 (es)
PT (7) PT3050564T (es)
RU (4) RU2013116405A (es)
SG (4) SG188573A1 (es)
SI (5) SI3348264T1 (es)
TR (1) TR201909249T4 (es)
TW (4) TWI591058B (es)
UA (1) UA112973C2 (es)
WO (4) WO2012037484A1 (es)
ZA (4) ZA201302194B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2395999B1 (en) 2009-02-13 2017-09-13 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
EP3659604A1 (en) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
CA2842866A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
US9095576B2 (en) 2011-11-21 2015-08-04 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
US20240287093A1 (en) * 2018-08-24 2024-08-29 Adlai Nortye Biopharma Co., Ltd. High activity sting protein agonist
MX2023012132A (es) * 2021-04-16 2023-10-25 Ads Therapeutics Llc Cofarmacos agonistas alfa-2 adrenergicos conjugados con farmacos agonistas muscarinicos.
WO2024167962A1 (en) * 2023-02-08 2024-08-15 Whitecap Biosciences Llc Alpha-2-adrenergic agonists for improving vision

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0642332B1 (en) 1992-05-13 1997-01-15 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
EP0729459B1 (en) 1993-11-15 2003-03-12 Schering Corporation Phenyl-alkyl imidazoles as h3-receptor antagonists
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
MXPA05012679A (es) * 2003-05-27 2006-02-08 Sod Conseils Rech Applic Nuevos derivados de imidazoles, su preparacion y su uso como medicamento.
JP2007528020A (ja) * 2003-07-14 2007-10-04 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 投影装置
KR20060126448A (ko) 2003-09-12 2006-12-07 알러간, 인코포레이티드 통증 및 다른 알파 2 아드레날린 매개 증상을 치료하기위한 방법 및 조성물
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
JP4955543B2 (ja) * 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
BRPI0516083A (pt) * 2004-09-24 2008-08-19 Allergan Sales Inc 4-(fenilmetil e 4-fenilmetil substituìdo)-imidazol-2-tionas que atuam como agonistas alfa2 adrenérgicos
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
US20110306635A1 (en) 2009-02-06 2011-12-15 Allergan ,Inc. Pyridine compounds as subtype selective modulators of alpha2b and /or alpha 2c adrenergic receptors
EP2395999B1 (en) * 2009-02-13 2017-09-13 Allergan, Inc. Pharmaceutical compositions comprising (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Also Published As

Publication number Publication date
ES2737230T3 (es) 2020-01-10
EP3050563B1 (en) 2018-05-09
AU2011301856A1 (en) 2013-05-02
CN103221045A (zh) 2013-07-24
BR112013006320A2 (pt) 2016-06-21
IL225281A0 (en) 2013-06-27
JP2013537237A (ja) 2013-09-30
US8492422B2 (en) 2013-07-23
US8653123B2 (en) 2014-02-18
DK3348264T3 (da) 2020-03-23
AR083020A1 (es) 2013-01-23
EP3659600A1 (en) 2020-06-03
SI3050563T1 (sl) 2018-10-30
TW201305117A (zh) 2013-02-01
DK2616069T3 (en) 2016-12-19
US20120149746A1 (en) 2012-06-14
WO2012037453A1 (en) 2012-03-22
US20120136036A1 (en) 2012-05-31
MX2013003009A (es) 2013-06-28
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
EP3698789A1 (en) 2020-08-26
CA3122745A1 (en) 2012-03-22
CN103200941A (zh) 2013-07-10
ES2593612T3 (es) 2016-12-12
SG188573A1 (en) 2013-04-30
EP3348264A1 (en) 2018-07-18
KR102104760B1 (ko) 2020-04-27
MY191369A (en) 2022-06-20
DK3050563T3 (en) 2018-08-13
CN103200941B (zh) 2015-12-16
BR112013006352A2 (pt) 2016-06-28
EP3348264B1 (en) 2020-01-01
EP2616069A1 (en) 2013-07-24
BR112013006320B1 (pt) 2022-08-30
CN103200942A (zh) 2013-07-10
PT3053576T (pt) 2018-10-08
ES2760920T3 (es) 2020-05-18
US8492557B2 (en) 2013-07-23
HK1257416A1 (zh) 2019-10-18
ES2607084T3 (es) 2017-03-29
CA2811559A1 (en) 2012-03-22
MY168763A (en) 2018-12-04
CA2812191C (en) 2021-04-13
SI3338777T1 (sl) 2020-08-31
IL225278A0 (en) 2013-06-27
ES2687420T3 (es) 2018-10-25
TW201240661A (en) 2012-10-16
DK3053576T3 (en) 2018-08-20
CA2812191A1 (en) 2012-03-22
KR20190022895A (ko) 2019-03-06
MY161607A (en) 2017-04-28
DK3338777T3 (da) 2020-04-20
RU2013116403A (ru) 2014-10-27
WO2012037499A1 (en) 2012-03-22
SG188570A1 (en) 2013-04-30
TR201909249T4 (tr) 2019-07-22
CN103209694A (zh) 2013-07-17
EP3636263B1 (en) 2021-11-03
PT3050564T (pt) 2019-12-11
CL2013000735A1 (es) 2013-11-29
MX2013003004A (es) 2013-06-28
PL2616068T3 (pl) 2016-11-30
KR101840501B1 (ko) 2018-05-04
RU2612351C2 (ru) 2017-03-07
EP3050564A1 (en) 2016-08-03
CN105412092B (zh) 2020-11-17
MY173846A (en) 2020-02-24
EP2616068B1 (en) 2016-07-13
HK1185540A1 (zh) 2014-02-21
PL3050563T3 (pl) 2018-12-31
IL225282A0 (en) 2013-06-27
EP3050564B1 (en) 2019-09-04
CA3116249A1 (en) 2012-03-22
EP2616066B1 (en) 2016-07-13
CA2812195A1 (en) 2012-03-22
TWI591058B (zh) 2017-07-11
PT2616068T (pt) 2016-09-13
PT3348264T (pt) 2020-04-02
US20150148394A1 (en) 2015-05-28
EP2616068A1 (en) 2013-07-24
JP2013540749A (ja) 2013-11-07
CY1122809T1 (el) 2021-05-05
WO2012037484A1 (en) 2012-03-22
EP2616067B1 (en) 2016-05-18
KR101840500B1 (ko) 2018-03-20
EP2616069B1 (en) 2016-11-16
KR20200044147A (ko) 2020-04-28
ES2613509T3 (es) 2017-05-24
IL225278A (en) 2015-11-30
PT3338777T (pt) 2020-05-06
NZ608751A (en) 2015-04-24
ZA201302193B (en) 2013-11-27
DK2616068T3 (en) 2016-08-29
CA3077732A1 (en) 2012-03-22
JP2013541527A (ja) 2013-11-14
ES2781681T3 (es) 2020-09-04
DK3050564T3 (da) 2019-11-25
CA3079450A1 (en) 2012-03-22
TW201240662A (en) 2012-10-16
SI3348264T1 (sl) 2020-07-31
US8501796B2 (en) 2013-08-06
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
JP6073229B2 (ja) 2017-02-01
CL2013000736A1 (es) 2013-07-12
MX2013003008A (es) 2013-06-28
AU2011301901A1 (en) 2013-05-02
ZA201302194B (en) 2013-11-27
US20120122945A1 (en) 2012-05-17
PL3050564T3 (pl) 2020-06-01
AU2011301847B2 (en) 2016-02-11
KR101952457B1 (ko) 2019-02-26
BR112013006355A2 (pt) 2016-06-28
SG188572A1 (en) 2013-04-30
KR102354097B1 (ko) 2022-01-20
RU2013116405A (ru) 2014-10-27
CL2013000734A1 (es) 2013-11-08
DK3078376T3 (da) 2019-06-24
US20130296394A1 (en) 2013-11-07
RU2013116541A (ru) 2014-10-27
HUE049573T2 (hu) 2020-10-28
JP6045495B2 (ja) 2016-12-14
SG188571A1 (en) 2013-04-30
WO2012037490A1 (en) 2012-03-22
EP2616066A1 (en) 2013-07-24
ES2788051T3 (es) 2020-10-20
PL3338777T3 (pl) 2020-07-13
SI3050564T1 (sl) 2020-02-28
IL225280A0 (en) 2013-06-27
PT2616069T (pt) 2016-12-06
AR083019A1 (es) 2013-01-23
AU2011301932A1 (en) 2013-05-02
AR083018A1 (es) 2013-01-23
SI3053576T1 (sl) 2018-11-30
CY1121024T1 (el) 2019-12-11
HK1185541A1 (zh) 2014-02-21
EP3053576A1 (en) 2016-08-10
CL2013000733A1 (es) 2013-08-23
MX2013003002A (es) 2013-06-28
CA2812197A1 (en) 2012-03-22
HUE048725T2 (hu) 2020-09-28
HUE039090T2 (hu) 2018-12-28
EP3636263A1 (en) 2020-04-15
CN105412092A (zh) 2016-03-23
EP3050563A1 (en) 2016-08-03
ES2684055T3 (es) 2018-10-01
HUE038698T2 (hu) 2018-11-28
PL3053576T3 (pl) 2018-11-30
EP3338777A1 (en) 2018-06-27
US20160354346A1 (en) 2016-12-08
KR20140003407A (ko) 2014-01-09
ZA201302288B (en) 2013-11-27
AU2011301932C1 (en) 2016-09-01
CA2812197C (en) 2024-01-02
PL2616069T3 (pl) 2017-04-28
PT3050563T (pt) 2018-10-01
ES2904479T3 (es) 2022-04-05
US20130289088A1 (en) 2013-10-31
PL3348264T3 (pl) 2020-08-24
KR20200091507A (ko) 2020-07-30
HK1185539A1 (zh) 2014-02-21
EP3078376A1 (en) 2016-10-12
BR112013006362A2 (pt) 2016-06-28
TW201305116A (zh) 2013-02-01
KR102139905B1 (ko) 2020-07-31
UA112973C2 (uk) 2016-11-25
JP2013537236A (ja) 2013-09-30
KR20130114140A (ko) 2013-10-16
US8853251B2 (en) 2014-10-07
EP3338777B1 (en) 2020-02-05
US20140057958A1 (en) 2014-02-27
HK1185538A1 (zh) 2014-02-21
US20120142746A1 (en) 2012-06-07
AU2011301932B2 (en) 2016-02-25
DK3636263T3 (da) 2022-01-10
EP3078376B1 (en) 2019-03-27
AU2011301856C1 (en) 2016-09-08
EP3053576B1 (en) 2018-05-16
AU2011301901B2 (en) 2016-02-11
CY1122958T1 (el) 2021-10-29
HUE047476T2 (hu) 2020-04-28
AU2011301847A1 (en) 2013-05-02
EP2616067A1 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
AR083017A1 (es) Prodrogas de ester de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
CO6251287A2 (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato -842
AR056764A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
CO6251260A2 (es) Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c.
RS52853B (en) SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
AR064389A1 (es) Derivados heterociclicos de nicotinamida utiles en el tratamiento de afecciones y enfermedades alergicas y respiratorias, y composiciones farmaceuticas que los contienen.
RS53627B1 (en) N- (3-Amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
RS52261B (en) AMIDOPHENOX INDASOLS AS A USEFUL C-MET INHIBITOR
RS54175B1 (en) BROMODOMEN INHIBITORS AND THEIR APPLICATION
RS53839B1 (en) SPIROCYCLES AS INHIBITORS OF 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
RS52661B (en) THERAPEUTIC MEANS
AR084001A1 (es) Monobactamas y su uso en el tratamiento de infecciones bacterianas
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
AR083026A1 (es) Derivados de ciclohexenona y composiciones para el tratamiento del cancer de pulmon
ATE457302T1 (de) Aromatische etherderivate als thrombin-hemmer
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
CO6241121A2 (es) Derivados de azapeptidps
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso

Legal Events

Date Code Title Description
FC Refusal